On August 14, 2026, RBC Capital reiterates its Outperform rating for Ascendis Pharma, a biopharmaceutical company that develops therapies using its TransCon technology. The bank raises its price target on the stock to $290.00 from $280.00. At the time of the rating, Ascendis Pharma's stock price is $246.23.
This positive analyst view follows the company's strong financial performance. For its second quarter of 2026, Ascendis Pharma reports total revenue of EUR 339 million. As highlighted by MarketBeat, this includes EUR 315 million in product revenue, which more than doubles from the prior-year period due to increasing demand for its therapies.
The revenue growth is driven by its three main products. YORVIPATH® generates €252 million, SKYTROFA® brings in €55 million, and YUVIWEL® contributes €8 million. According to a GlobeNewsWire report, the company also sees strong patient enrollment for YUVIWEL®, with over 220 unique patients in the U.S. through July.
The company reports a net profit of EUR 207 million for the quarter. Its operating profit stands at EUR 220 million, which is significantly helped by EUR 158 million in other income. This extra income comes from the sale of a priority review voucher, a coupon that can be sold to other companies for a faster FDA review.
Ascendis Pharma ends the quarter with a strong cash position of EUR 812 million. This is after using EUR 56 million for its share-repurchase program, where a company buys back its own stock from the market. The company also reports it has settled all of its convertible notes, a type of debt.
